Search details
1.
Safety and Efficacy of Istaroxime 1.0 and 1.5 µg/kg/min for Patients With Pre-Cardiogenic Shock.
J Card Fail
; 29(7): 1097-1103, 2023 07.
Article
in English
| MEDLINE | ID: mdl-37075941
2.
The pharmacokinetics and safety of darapladib in subjects with severe renal impairment.
Br J Clin Pharmacol
; 80(4): 654-61, 2015 Oct.
Article
in English
| MEDLINE | ID: mdl-25953363
3.
Physical activity in patients with stable coronary heart disease: an international perspective.
Eur Heart J
; 34(42): 3286-93, 2013 Nov.
Article
in English
| MEDLINE | ID: mdl-24014220
4.
Safety and efficacy of istaroxime in patients with acute heart failure-related pre-cardiogenic shock - a multicentre, randomized, double-blind, placebo-controlled, parallel group study (SEISMiC).
Eur J Heart Fail
; 24(10): 1967-1977, 2022 10.
Article
in English
| MEDLINE | ID: mdl-35867804
5.
Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial.
Diabetes Care
; 43(10): 2509-2518, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32694215
6.
Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia.
Drug Saf
; 32(3): 203-18, 2009.
Article
in English
| MEDLINE | ID: mdl-19338378
7.
Efficacy and safety of an albiglutide liquid formulation compared with the lyophilized formulation: A 26-week randomized, double-blind, repeat-dose study in patients with type 2 diabetes mellitus.
Diabetes Res Clin Pract
; 152: 125-134, 2019 Jun.
Article
in English
| MEDLINE | ID: mdl-31004676
8.
A Randomized, Double-Blind, Single-Dose, Crossover Study to Demonstrate the Bioequivalence of 2 Formulations of Albiglutide in Healthy Adult Participants.
Clin Pharmacol Drug Dev
; 8(3): 361-370, 2019 04.
Article
in English
| MEDLINE | ID: mdl-30063297
9.
Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial.
J Am Heart Assoc
; 6(10)2017 Oct 24.
Article
in English
| MEDLINE | ID: mdl-29066452
10.
Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease.
Int J Cardiol
; 245: 271-276, 2017 Oct 15.
Article
in English
| MEDLINE | ID: mdl-28735759
11.
Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease.
J Am Coll Cardiol
; 70(7): 813-826, 2017 Aug 15.
Article
in English
| MEDLINE | ID: mdl-28797349
12.
Tooth loss is independently associated with poor outcomes in stable coronary heart disease.
Eur J Prev Cardiol
; 23(8): 839-46, 2016 05.
Article
in English
| MEDLINE | ID: mdl-26672609
13.
Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging.
J Am Coll Cardiol
; 63(1): 86-8, 2014.
Article
in English
| MEDLINE | ID: mdl-23973698
14.
Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease
Int. j. cardiol
; Oct(245): 271-276, 2017.
Article
in English
| SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1063539
Results
1 -
14
de 14
1
Next >
>>